Hepatitis B and C
Management and Treatment
- Publisher's listprice GBP 115.00
-
58 201 Ft (55 430 Ft + 5% VAT)
The price is estimated because at the time of ordering we do not know what conversion rates will apply to HUF / product currency when the book arrives. In case HUF is weaker, the price increases slightly, in case HUF is stronger, the price goes lower slightly.
- Discount 20% (cc. 11 640 Ft off)
- Discounted price 46 561 Ft (44 344 Ft + 5% VAT)
Subcribe now and take benefit of a favourable price.
Subscribe
58 201 Ft
Availability
Estimated delivery time: In stock at the publisher, but not at Prospero's office. Delivery time approx. 3-5 weeks.
Not in stock at Prospero.
Why don't you give exact delivery time?
Delivery time is estimated on our previous experiences. We give estimations only, because we order from outside Hungary, and the delivery time mainly depends on how quickly the publisher supplies the book. Faster or slower deliveries both happen, but we do our best to supply as quickly as possible.
Product details:
- Edition number 2, New edition
- Publisher CRC Press
- Date of Publication 25 August 2004
- ISBN 9781841843698
- Binding Hardback
- No. of pages176 pages
- Size 234x156 mm
- Weight 544 g
- Language English
- Illustrations 50 Illustrations, black & white 0
Categories
Short description:
Chronic hepatitis B and C affect 520 million people worldwide, and are a major cause of chronic liver disease and of mortality, despite the efficacy of the vaccine. Hepatitis B and C: Management and Treatment second edition provides a practical explanation of the natural history and management of the disease, and examines the benefits of the most recent drugs, and their effects, whether used in isolation or as part of a combination therapy. This second edition expands the coverage of treatment of various difficult-to-treat patients and will be a welcome guide to the physician in both clinical decision-making and in explaining the benefits and side-effects to the patient.
MoreLong description:
Chronic hepatitis B and C affect 520 million people worldwide, and are a major cause of chronic liver disease and of mortality, despite the efficacy of the vaccine. Hepatitis B and C: Management and Treatment second edition provides a practical explanation of the natural history and management of the disease, and examines the benefits of the most recent drugs, and their effects, whether used in isolation or as part of a combination therapy. This second edition expands the coverage of treatment of various difficult-to-treat patients and will be a welcome guide to the physician in both clinical decision-making and in explaining the benefits and side-effects to the patient.
MoreTable of Contents:
Section 1: Hepatitis C. Introduction. Natural History of Hepatitis C: Epidemiology. Natural History of Hepatitis C: Hepatic Manifestations. Natural History of Hepatitis C: Extra-hepatic Manifestations and Quality of Life. Management Protocols in Chronic Hepatitis C. Management of Relapsers and Non Responders, Maintenance Therapy. Management of Patients with Cirrhosis. Management of Patients Co-infected by HCV and HIV. Management of HCV Infection Post Liver Transplantation. Management of Patients with Renal Disease. Safety of Interferon, Pegylated Interferon and Ribavirin. Who Need to be Treated? Cost-effectiveness of Treatment. Management of Acute Hepatitis C. Difficult-to-treat Patients. Practical Guidelines for the Management of Hepatitis C. New Drugs in Development. Section 2: Hepatitis B. Introduction. Natural History of Hepatitis B: Epidemiology. Natural History of Hepatitis B: Hepatic Manifestations. Natural History of Hepatitis B: Extra-hepatic Manifestations and Quality of Life. The Goal of Treatment in Chronic Hepatitis B. Efficacy of Interferon and Pegylated Interferon. Efficacy of Lamivudine. Efficacy of Adefovir. Comparison Between Lamivudine, Interferon and Adefovir, and Combinations. Safety of Lamivudine. Safety of Adefovir. New Drugs in Development. First Line Treatment of Chronic Hepatitis B: Adefovir, Lamivudine or Interferon? Who Need to be Treated and How to Explain the Goals to the Patient? Management of Relapsers and Non Responders. Management of Patients Co-infected by HBV and HIV. Management of Transplanted Patients Infected by HBV. Cost-effectiveness of Treatment. Section 3: Biochemical Markers, an Alternative to Liver Biopsies. Advantage and Limits of Liver Biopsy. Advantage and Limits of Biochemical Markers.
More
